Lexington, MA, United States of America

Thomas Wai-Ho Lee

This inventor holds 17 USPTO granted patents and 30 published patent applications, plus 3 CIPO patents and 11 EPO patents. Top assignees: Cyclerion Therapeutics, Inc., Ironwood Pharmaceuticals, Inc., Tisento Therapeutics Inc.. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Wai-Ho Lee. Retrieved from https://idiyas.com/inventor/thomas-wai-ho-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 

% Patents Active = 94.1

 

 

Average Co-Inventor Count = 10.1

ph-index = 6

Forward Citations = 80(Granted Patents)


Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents

Title: The Inventor Thomas Wai-Ho Lee

Introduction: Thomas Wai-Ho Lee is a renowned inventor based in Lexington, MA (US) known for his groundbreaking contributions to various fields.

Latest Patents: Thomas Wai-Ho Lee holds several patents in the areas of technology and healthcare, showcasing his innovative mindset and problem-solving abilities.

Career Highlights: With a career spanning over two decades, Thomas Wai-Ho Lee has worked with leading research institutions and companies, developing cutting-edge solutions that have had a significant impact on the industry.

Collaborations: Throughout his career, Thomas Wai-Ho Lee has collaborated with top experts in the field, fostering a culture of innovation and excellence in all his projects.

Conclusion: Thomas Wai-Ho Lee's dedication to innovation and his passion for creating solutions to complex problems have solidified his reputation as a pioneering inventor in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…